Adrenergic agonists (-agonists) are commonly used to treat respiratory syncytial virus (RSV) bronchiolitis but are generally ineffective for unknown reasons. We have previously shown that RSV strain A2 inhibits bronchoalveolar epithelial responses to -agonists in a BALB/c mouse model by inducing heterologous keratinocyte cytokine (KC)/CXCR2-mediated desensitization of epithelial  2-adrenergic receptors. The aim of the current study was to determine whether RSV also induces airway insensitivity to -agonists. Total lung resistance (R) was measured in anesthetized female BALB/c mice undergoing mechanical ventilation on a flexiVent computer-controlled piston ventilator. Data were analyzed using the single-compartment model. Infection with RSV A2 did not induce airway hyperresponsiveness to increasing doses of the nebulized cholinergic agonist methacholine (MCh) at any time point after RSV infection. Prenebulization with the -agonist terbutaline (100 M) significantly attenuated bronchoconstrictive responses to 20 and 50 mg/ml MCh in uninfected mice and in mice infected with RSV 4 -8 days postinfection (d.p.i.). However, in mice infected with replication-competent, but not UV-inactivated, RSV for 2 days, significant terbutaline insensitivity was found. Terbutaline insensitivity at 2 d.p.i. could be reversed by systemic preinfection treatment with neutralizing anti-CXCR2 antibodies, which reduced bronchoalveolar lavage (BAL) neutrophil counts but did not alter viral replication, BAL KC levels, or lung edema. Terbutaline insensitivity was also reversed by postinfection nebulization with neutralizing anti-KC or anti-CXCR2 antibodies and could be replicated in normal, uninfected mice by nebulization with recombinant KC. These data suggest that KC/CXCR2-mediated airway insensitivity to -agonists may underlie the modest utility of these drugs as bronchodilators in therapy for acute RSV bronchiolitis. CXCL8; CXCR2; keratinocyte cytokine; airway hyperresponsiveness RESPIRATORY SYNCYTIAL VIRUS (RSV) is the most common cause of lower respiratory tract disease in infants and children worldwide (36). In the United States, 50 -70% of infants are infected with RSV in the first year of life (29) with bronchiolitis now accounting for approximately 75,000 -125,000 hospitalizations annually (32, 33). RSV-related mortality has decreased over the last 20 yr, but RSV remains the leading cause of viral deaths in infants (33). In addition, this virus is increasingly recognized as being underdiagnosed as a cause of communityacquired lower respiratory tract infections among adults (10) and is a significant cause of excess morbidity and mortality in immune-compromised adults (41). Indeed, recent studies suggest that RSV has a disease impact comparable with that of nonpandemic influenza A in the elderly (9).